VEGFA and colorectal carcinoma: Currently, targeted drugs for CRC treatment mainly include anti-vascular endothelial growth factor (VEGF) (bevacizumab, aflibercept, ramucirumab), anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab) and multi-kinase inhibitors (regorafenib) [7].